Metropolitan Life Insurance CO Brooklyn Immuno Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$4.17 - $9.79 $35,907 - $84,301	-8,611 Closed	0 $0
Q3 2021 Jun 21, 2023	BUY	$8.86 - $17.05 $76,293 - $146,817	8,611 New	8,611 $80,000
Q3 2021 Mar 30, 2023	BUY	$8.86 - $17.05 $3,003 - $5,779	339 Added 4.1%	8,611 $80,000
Q3 2021 Nov 15, 2021	BUY	$8.86 - $17.05 $3,003 - $5,779	339 Added 4.1%	8,611 $80,000
Q2 2021 Jun 21, 2023	BUY	$3.75 - $78.5 $31,020 - $649,352	8,272 New	8,272 $148,000
Q2 2021 Mar 30, 2023	BUY	$3.75 - $78.5 $31,020 - $649,352	8,272 New	8,272 $148,000
Q2 2021 Aug 16, 2021	BUY	$3.75 - $78.5 $31,020 - $649,352	8,272 New	8,272 $149,000

1.21M

Ticker BTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,825,700
Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.